What does this research mean for the field?

Idarucizumab reversal expands reperfusion options by enabling both intravenous thrombolysis and endovascular therapy in NOAC-treated patients experiencing post-ablation stroke. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

November 21, 2025Neurology International1 citationsOpen Access

View Full Paper

Post-Ablation Stroke Despite NOAC Use: Successful Reperfusion Therapy After Dabigatran Reversal with Incidental Discovery of a Large MCA Aneurysm—A Case Report

SSS. SariHualien Tzu Chi Medical Center WCWei‐Tso ChenHualien Tzu Chi Medical Center CLChien-Hui LeeTzu Chi University

Key Result

Idarucizumab reversal of dabigatran expands stroke reperfusion options by enabling both IVT and EVT in NOAC-treated patients.

Structured PICO

Population

1 patient with post-ablation stroke despite dabigatran use

Intervention

Idarucizumab reversal followed by intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT)

Outcome

Successful reperfusion

Idarucizumab reversal can safely enable both intravenous thrombolysis and endovascular thrombectomy in patients experiencing acute ischemic stroke while on dabigatran.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

This case illustrates how idarucizumab reversal expands reperfusion options by enabling both IVT and EVT in NOAC-treated patients and highlights the diagnostic role of EVT in revealing underlying vascular pathology, emphasizing the need for individualized post-procedural antithrombotic management.

Ask AI

Helpful

Bookmark

View Full Paper

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Sari et al. (Fri,) reported a other. Idarucizumab reversal of dabigatran expands stroke reperfusion options by enabling both IVT and EVT in NOAC-treated patients.

synapsesocial.com/papers/6a085f843d5e33e4691083cd https://doi.org/https://doi.org/10.3390/neurolint17120190